|
|
|
|
|
|
24.04.25 - 15:36
|
Merck & Co: Gewinnprognose gekappt – Halozyme klagt (Der Aktionaer)
|
|
Der US-amerikanische Pharma-Riese Merck & Co muss seine Ziele für das laufende Geschäftsjahr nach unten anpassen. Vor allem das schwächelnde Geschäft mit dem Impfstoff Gardasil in China belastet das Zahlenwerk des Konzerns. Darüber hinaus wird das im Dow Jones gelistete Unternehmen von Halozyme Therapeutics verklagt....
|
|
24.04.25 - 15:36
|
Stock Movers: Merck Up, Pepsi, American Airlines Fall On Profit Outlook (Bloomberg)
|
|
Merck (MRK) shares are higher in spite of the company cutting its adjusted earnings per share forecast for the year and saying it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US and China. Still, the company's first-quarter results beat estimates.
PepsiCo (PEP) shares are down after lowering its full-year profit outlook due to unpredictable US trade policy and worsening consumer sentiment, driving up costs and denting demand for its products.
American Air (AAL) shares dropped after it withdrew its full-year earnings outlook due to economic uncertainty. The airline cited weak domestic leisure travel and economic worries. (Source: Bloomberg)...
|
|
|
|
|
24.04.25 - 13:24
|
ROUNDUP: Merck Trims FY25 Adj. EPS Outlook (AFX)
|
|
KENILWORTH (NJ) (dpa-AFX) - While reporting financial results for the first quarter on Wednesday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, trimm......
|
|
|
|
|
|
04.02.25 - 15:48
|
Merck Stock Down 8% On Weak Outlook, Q4 Results Miss Estimates (RTTNews)
|
|
Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the fourth quarter compared to a loss last year, reflecting improved gross margins, sharply lower R&D expenses and 7 percent sales growth. However, both adjusted earnings per share and quarterly sales missed analysts' estimates. The company also provided a weak guidance for the full-year 2025....
|
|
|
04.02.25 - 13:51
|
Merck & Co: Ausblick enttäuscht – Aktie bricht ein (Der Aktionaer)
|
|
Der amerikanische Pharma-Riese Merck & Co hat die Zahlen für das abgelaufene vierte Quartal respektive Gesamtjahr 2024 vorgelegt und einen Ausblick auf das neue Fiskaljahr abgegeben. Die Prognose sowohl für den Umsatz als auch das Ergebnis je Aktie sorgt für eine Enttäuschung....
|
|
|
04.02.25 - 13:13
|
ROUNDUP: Merck Stock Down 8% On Weak FY25 Outlook (AFX)
|
|
KENILWORTH (NJ) (dpa-AFX) - While reporting financial results for the fourth quarter on Tuesday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, initia......
|
|